Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Short Interest Update

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) saw a significant decrease in short interest in the month of June. As of June 30th, there was short interest totaling 6,372 shares, a decrease of 35.7% from the June 15th total of 9,904 shares. Based on an average trading volume of 8,436 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.1% of the shares of the company are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.44% of the company’s stock.

Cryo-Cell International Stock Down 0.6%

Cryo-Cell International stock opened at $3.46 on Friday. The business has a 50-day simple moving average of $3.52 and a two-hundred day simple moving average of $3.45. The company has a market cap of $27.89 million, a P/E ratio of -11.53 and a beta of 0.49. Cryo-Cell International has a 52-week low of $2.72 and a 52-week high of $5.43.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $0.07 earnings per share for the quarter. The business had revenue of $7.78 million during the quarter.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.